Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.72 |
| ▸ | MAPT | P10636 | 5/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.72 |
| ▸ | NSD2 | O96028 | 1/20 | 0.72 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CASP6 | P55212 | 1/20 | 0.46 |
| ▸ | PLAU | P00749 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | CASP1 | P29466 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | PRKCI | P41743 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 4/20 | 0.40 |
| ▸ | MAOB | P27338 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8100661 | 0.98 | KDM4E (0.70) | KDM4EMAPTALDH1A1NSD2LMNA | |
| SCHEMBL30475995 | 0.87 | KDM4E (0.56) | KDM4EMAPTALDH1A1NSD2LMNA | |
| SCHEMBL22130148 | 0.85 | KDM4E (0.59) | KDM4EMAPTALDH1A1NSD2TP53 | |
| SCHEMBL1489105 | 0.84 | KDM4E (1.00) | KDM4EMAPTALDH1A1NSD2LMNA | |
| Quinoline SCHEMBL27606982 | 0.83 | ALDH1A1 (0.59) | KDM4EMAPTALDH1A1NSD2POLB | |
| Hydrochloric Acid SCHEMBL8100733 | 0.82 | KDM4E (0.96) | KDM4EMAPTALDH1A1NSD2LMNA | |
| SCHEMBL422738 | 0.78 | KDM4E (0.50) | KDM4EMAPTALDH1A1NSD2MAOA | |
| SCHEMBL16478021 | 0.78 | PLAU (0.45) | KDM4EMAPTALDH1A1NSD2LMNA | |
| SCHEMBL22032485 | 0.77 | KDM4E (0.49) | KDM4EMAPTALDH1A1NSD2LMNA | |
| SCHEMBL24814672 | 0.76 | KDM4E (0.49) | KDM4EMAPTALDH1A1NSD2MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 311 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117186077-A | 3-triazolylmethyl-1, 3, 5-triazine-2, 4-dione compound and preparation method and application thereof | 陕西盘龙药业集团股份有限公司 | 2023-12-08 | — | — | CN | claimed |
| US-20230391736-A1 | 3-TETRAZOLYLMETHYL-1,3,5-TRIAZIN-2,4-DIONE COMPOUND INHIBITING CORONAVIRUS 3CL PROTEASE ACTIVITY AND PREPARATION METHOD AND USE THEREOF | Shaanxi Panlong Pharmaceutical Co., Ltd. (CN) | 2023-12-07 | — | — | US | claimed |
| EP-0904769-B1 | Keratin fibre dye compositions containing Indazole amine derivatives and dyeing method | OREAL (FR) | 2002-09-25 | — | — | EP | claimed |
| US-6027538-A | OXIDATION DYEING OF KERATINOUS FIBERS CONTAINING AT LEAST ONE COUPLER SELECTED FROM INDAZOLEAMINE DERIVATIVES AND AT LEAST ONE OXIDATION BASE; POWERFUL, NOT VERY SELECTIVE HAIR DYES WHICH ARE CAPABLE OF GENERATING INTENSE COLOR | L'OREAL S.A. (FR) | 2000-02-22 | — | — | US | claimed |
| EP-0904769-A1 | Keratin fibre dye compositions containing Indazole amine derivatives and dyeing method | L'OREAL (FR) | 1999-03-31 | — | — | EP | claimed |
| CN-122036626-A | Pyrimidine-2 (1H) -ketone derivative, pharmaceutical composition and application thereof | 上海青润医药科技有限公司 | 2026-05-15 | — | — | CN | disclosed |
| EP-4724443-A1 | PYRAZOLO-PYRIMIDINONE COMPOUNDS FOR USE IN METHODS OF INHIBITING WEE1 A KINASE | Acrivon Therapeutics, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| US-20250388591-A1 | TRICYCLIC COMPOUNDS AND USES THEREOF | CSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD (CN) | 2025-12-25 | — | — | US | disclosed |
| WO-2025245484-A1 | FOXN1 ACTIVATORS | THYMOFOX INC. (US) | 2025-11-27 | — | — | WO | disclosed |
| US-20250282748-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2025-09-11 | — | — | US | disclosed |
| WO-2025111547-A1 | 2,3-DIHYDROPYROLLOPYRIDINE CARBOXAMIDE COMPOUNDS AND METHODS OF USE THEREOF | RGENTA THERAPEUTICS, INC. (US) | 2025-05-30 | — | — | WO | disclosed |
| EP-4545531-A1 | TRICYCLIC COMPOUNDS AND USES THEREOF | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) | 2025-04-30 | — | — | EP | disclosed |
| US-20040138286-A1 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-07-15 | — | — | US | disclosed |
| EP-1403255-A1 | Rho KINASE INHIBITORS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-03-31 | — | — | EP | disclosed |
| US-20040029902-A1 | Antiinflamamtory agents | MIDCAP FINANCIAL TRUST | 2004-02-12 | — | — | US | disclosed |
| WO-2003063794-A2 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2003-08-07 | — | — | WO | disclosed |
| WO-2003030909-A1 | 2- AND 4-AMINOPYRIMIDINES N-SUBSTTITUDED BY A BICYCLIC RING FOR USE AS KINASE INHIBITORS IN THE TREATMENT OF CANCER | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-04-17 | — | — | WO | disclosed |
| EP-0904769-B1 | Keratin fibre dye compositions containing Indazole amine derivatives and dyeing method | OREAL (FR) | 2002-09-25 | — | — | EP | disclosed |
| US-6027538-A | OXIDATION DYEING OF KERATINOUS FIBERS CONTAINING AT LEAST ONE COUPLER SELECTED FROM INDAZOLEAMINE DERIVATIVES AND AT LEAST ONE OXIDATION BASE; POWERFUL, NOT VERY SELECTIVE HAIR DYES WHICH ARE CAPABLE OF GENERATING INTENSE COLOR | L'OREAL S.A. (FR) | 2000-02-22 | — | — | US | disclosed |
| EP-0904769-A1 | Keratin fibre dye compositions containing Indazole amine derivatives and dyeing method | L'OREAL (FR) | 1999-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388591-A1 | TRICYCLIC COMPOUNDS AND USES THEREOF | MAT2A, MAT1A, MAT2B | KDM4E 2313/4885MAPT 90/4885ALDH1A1 449/4885 |
| US-20040029902-A1 | Antiinflamamtory agents | FCER2, FCGR1A, HNMT | KDM4E 2664/4885MAPT 4330/4885ALDH1A1 2723/4885 |
| US-20250282748-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | OGFOD1, VASP, PNPO | KDM4E 2356/4885MAPT 4438/4885ALDH1A1 2345/4885 |
| US-20040138286-A1 | Rho kinase inhibitors | ROCK1, ROCK2, ARHGDIA | KDM4E 1759/4885MAPT 3261/4885ALDH1A1 3541/4885 |
| US-20230391736-A1 | 3-TETRAZOLYLMETHYL-1,3,5-TRIAZIN-2,4-DIONE COMPOUND INHIBITING CORONAVIRUS 3CL PROTEASE ACTIVITY AND PREPARATION METHOD AND USE THEREOF | ACE2, ACE, GTF3C3 | KDM4E 1325/4885MAPT 3724/4885ALDH1A1 2242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.